Comparative Pharmacology
Head-to-head clinical analysis: BIMZELX versus TRAVOPROST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIMZELX versus TRAVOPROST.
BIMZELX vs TRAVOPROST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BIMZELX (bimekizumab) is a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin-17A (IL-17A) and interleukin-17F (IL-17F), inhibiting their binding to the IL-17 receptor and subsequent pro-inflammatory signaling.
Travoprost is a synthetic prostaglandin F2α analog that acts as a selective FP receptor agonist. By binding to FP prostanoid receptors, it increases uveoscleral outflow of aqueous humor, reducing intraocular pressure.
Subcutaneous injection: 160 mg (two 80 mg injections) at week 0, week 2, week 4, then every 4 weeks.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
None Documented
None Documented
Clinical Note
moderatePirlindole + Travoprost
"Pirlindole may increase the hypotensive activities of Travoprost."
Clinical Note
moderateTiaprofenic acid + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Carprofen."
Clinical Note
moderateBosentan + Travoprost
Terminal elimination half-life is approximately 26 days (range 22–29 days) across approved doses; supports every 4-week subcutaneous dosing.
Terminal elimination half-life is approximately 45 minutes (range 17–86 minutes) for travoprost free acid in plasma; clinical effect (IOP reduction) persists longer due to prolonged receptor binding.
Bimekizumab is a monoclonal antibody that is degraded into small peptides and amino acids via general protein catabolism; no renal or biliary excretion of intact antibody. Fecal excretion of degraded fragments is minor (<1%).
Renal (approximately 20% as unchanged drug and free acid metabolites); biliary/fecal (about 60% as metabolites)
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog
"Bosentan may increase the hypotensive activities of Travoprost."